|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists
La Merie Publishing, Sep 2009, Pages: 133
The present Competitive Intelligence Report about VEGF and VEGF-R agonists and antagonists provides a competitor evaluation in the field of VEGF and its receptor targeting molecules for treatment of cancer, AMD and for neuroprotection as of September 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The importance of tumor angiogenesis in tumor biology is now widely accepted and has emerged as a valid therapeutic target in oncology. Vascular endothelial growth factor (VEGF) represents a key mediator of tumor-initiated angiogenesis and the first target of antiangiogenesis agents introduced in clinical practice. VEGF and VEGF receptor antagonists have revolutionized therapy of cancer which is reflected by their outstanding commercial success: 2008 sales of US$ 6.4 bln only in oncology. VEGF blockers found further use in inhibiting or even reversing angiogenesis in neovascular (wet) age-related macular degeneration (AMD). This market already reached US$ 1.8 bln in 2008.
Obviously, the total market size of US$ 8.2 bln for VEGF and VEGF receptor (VEGF-R) antagonists has attracted many companies to invest in follow-up and next generation molecules targeting VEGF and VEGF-R. The clinically validated target provides a low risk opportunity for new technologies with proteins, RNA, antibodies and vaccines for validation of the technologies. Multi-target receptor tyrosine kinase (RTK) inhibitors are another possibility to further increase the efficacy of VEGF-R antagonists by adding anti-proliferative or anti-migration effects. In contrast to antagonism of angiogenesis, the growth factor activity of VEGF has created a high level of interest for neuroprotection and several approaches are in clinical evaluation.
The report includes a compilation of current active projects in research and development of molecules targeting VEGF or VEGF receptor. In addition, the report lists company-specific R&D pipelines of VEGF/R targeting molecules. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Competitor Analysis: PDGF-R Agonists and Antagonists
Competitor Analysis - Cancer Antibodies in Early Clinical Development
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
Competitor Analysis: FGF-R Agonists and Antagonists
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report
Competitor Analysis - Toll-Like Receptor (TLR) Agonists and Antagonists 2010
Oncology Pipeline Database
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
|
|
|
|
